Clinical trial
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim…
NCT00089115 · Favrille, Industry · Terminated
Key facts
| NCT number | NCT00089115 |
|---|---|
| Title | Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Favrille, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim |
| Start date | Jul 1, 2004 |
| First posted | Aug 5, 2004 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: